By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Gain Therapeutics, Inc.

Gain Therapeutics, Inc. (GANX)

NASDAQ Currency in USD
$1.72
-$0.01
-0.58%
Last Update: 11 Sept 2025, 20:00
$61.83M
Market Cap
-1.83
P/E Ratio (TTM)
Forward Dividend Yield
$1.36 - $3.19
52 Week Range

GANX Stock Price Chart

Explore Gain Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze GANX price movements and trends.

GANX Company Profile

Discover essential business fundamentals and corporate details for Gain Therapeutics, Inc. (GANX) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

19 Mar 2021

Employees

23.00

CEO

Gene Mack

Description

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

GANX Financial Timeline

Browse a chronological timeline of Gain Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 12 May 2026

Upcoming earnings on 13 Nov 2025

EPS estimate is -$0.15.

Earnings released on 12 Aug 2025

EPS came in at -$0.19 falling short of the estimated -$0.17 by -11.76%.

Earnings released on 14 May 2025

EPS came in at -$0.16 matching the estimated -$0.16.

Earnings released on 27 Mar 2025

EPS came in at -$0.11 surpassing the estimated -$0.18 by +38.89%.

Earnings released on 14 Nov 2024

EPS came in at -$0.17 surpassing the estimated -$0.23 by +26.09%.

Earnings released on 8 Aug 2024

EPS came in at -$0.42 falling short of the estimated -$0.31 by -35.48%.

Earnings released on 14 May 2024

EPS came in at -$0.22 surpassing the estimated -$0.30 by +26.67%.

Earnings released on 26 Mar 2024

EPS came in at -$0.29 surpassing the estimated -$0.32 by +9.38%, while revenue for the quarter reached $64.80K , missing expectations by -79.75%.

Earnings released on 14 Nov 2023

EPS came in at -$0.37 surpassing the estimated -$0.47 by +21.28%.

Earnings released on 10 Aug 2023

EPS came in at -$0.62 falling short of the estimated -$0.33 by -87.88%.

Earnings released on 12 May 2023

EPS came in at -$0.43 falling short of the estimated -$0.40 by -7.50%, while revenue for the quarter reached $55.18K , beating expectations by +451.80%.

Earnings released on 23 Mar 2023

EPS came in at -$0.39 falling short of the estimated -$0.37 by -5.41%, while revenue for the quarter reached $140.11K , beating expectations by +1.30K%.

Earnings released on 10 Nov 2022

EPS came in at -$0.38 surpassing the estimated -$0.46 by +17.39%.

Earnings released on 8 Aug 2022

EPS came in at -$0.43 falling short of the estimated -$0.35 by -22.86%, while revenue for the quarter reached $95.10K , beating expectations by +200.32%.

Earnings released on 16 May 2022

EPS came in at -$0.28 surpassing the estimated -$0.34 by +17.65%, while revenue for the quarter reached $45.01K , beating expectations by +15.40%.

Earnings released on 24 Mar 2022

EPS came in at -$0.25 surpassing the estimated -$0.49 by +48.98%, while revenue for the quarter reached $36.34K , missing expectations by -29.57%.

Earnings released on 12 Nov 2021

EPS came in at -$0.39 falling short of the estimated -$0.34 by -14.71%, while revenue for the quarter reached $27.35K , beating expectations by +100.74%.

Earnings released on 11 Aug 2021

EPS came in at -$0.30 surpassing the estimated -$0.31 by +3.23%, while revenue for the quarter reached $89.17K , beating expectations by +5.84%.

Earnings released on 10 May 2021

EPS came in at -$0.50 falling short of the estimated -$0.21 by -138.10%, while revenue for the quarter reached $5.27K , beating expectations by +6.11%.

Earnings released on 22 Mar 2021

EPS came in at -$0.30 , while revenue for the quarter reached $6.70K .

Earnings released on 31 Dec 2020

EPS came in at -$0.15 , while revenue for the quarter reached $9.14K .

GANX Stock Performance

Access detailed GANX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run